[go: up one dir, main page]

WO1996012496A1 - Utilisation de n-[(1s,trans)-2-hydroxycyclopentyl]-adenosine pour reduire une blessure myocardique - Google Patents

Utilisation de n-[(1s,trans)-2-hydroxycyclopentyl]-adenosine pour reduire une blessure myocardique Download PDF

Info

Publication number
WO1996012496A1
WO1996012496A1 PCT/EP1995/004089 EP9504089W WO9612496A1 WO 1996012496 A1 WO1996012496 A1 WO 1996012496A1 EP 9504089 W EP9504089 W EP 9504089W WO 9612496 A1 WO9612496 A1 WO 9612496A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
acceptable salt
solvate
physiologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1995/004089
Other languages
English (en)
Inventor
James Louttit
Mark Francis Gurden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to AU38434/95A priority Critical patent/AU3843495A/en
Publication of WO1996012496A1 publication Critical patent/WO1996012496A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composé de la formule (1a) ou des sels ou solvates de celui-ci, acceptables sur le plan physiologique, destinés à la réduction de l'infarctus du myocarde consécutif à une ischémie myocardique sévère.
PCT/EP1995/004089 1994-10-20 1995-10-18 Utilisation de n-[(1s,trans)-2-hydroxycyclopentyl]-adenosine pour reduire une blessure myocardique Ceased WO1996012496A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU38434/95A AU3843495A (en) 1994-10-20 1995-10-18 Use of n-{(1s,trans)-2-hydroxycyclopentyl}-adenosine for reducing myocardial injury

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9421133A GB9421133D0 (en) 1994-10-20 1994-10-20 Medicaments
GB9421133.1 1994-10-20

Publications (1)

Publication Number Publication Date
WO1996012496A1 true WO1996012496A1 (fr) 1996-05-02

Family

ID=10763123

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/004089 Ceased WO1996012496A1 (fr) 1994-10-20 1995-10-18 Utilisation de n-[(1s,trans)-2-hydroxycyclopentyl]-adenosine pour reduire une blessure myocardique

Country Status (3)

Country Link
AU (1) AU3843495A (fr)
GB (1) GB9421133D0 (fr)
WO (1) WO1996012496A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999017784A1 (fr) * 1997-10-07 1999-04-15 Regents Of The University Of California Corporation Traitement de la vasculopathie peripherique obliterante et de la coronarite au moyen de conbinaisons d'heparine et d'un agoniste a2 adenosine, ou au moyen d'adenosine
US5972903A (en) * 1997-10-07 1999-10-26 Regents Of The University Of California Corporation Method for promoting angiogenesis using heparin and adenosine
US6476351B1 (en) * 1996-01-05 2002-11-05 Lazare Kaplan International, Inc. Laser marking system
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0322242A2 (fr) * 1987-12-23 1989-06-28 Glaxo Group Limited Dérivés d'adénosine
WO1992020346A1 (fr) * 1991-05-22 1992-11-26 Vanderbilt University Methode et composition permettant de reduire la blessure du myocarde due au retablissement de la circulation
WO1993023418A1 (fr) * 1992-05-14 1993-11-25 Novo Nordisk A/S Derives de la purine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0322242A2 (fr) * 1987-12-23 1989-06-28 Glaxo Group Limited Dérivés d'adénosine
WO1992020346A1 (fr) * 1991-05-22 1992-11-26 Vanderbilt University Methode et composition permettant de reduire la blessure du myocarde due au retablissement de la circulation
WO1993023418A1 (fr) * 1992-05-14 1993-11-25 Novo Nordisk A/S Derives de la purine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. TSUCHIDA: "Pretreatment with the adenosine A1 selective agonist, 2-chloro-N6-cyclopentyladenosine (CCPA), causes a sustained limitation of infarct size in rabbits.", CARDIOVASC. RES., vol. 27, no. 4, 1993, pages 652 - 656 *
E.D. NORTON: "The effects of intravenous infusions of selective adenosine A1-receptor and A2-receptor agonists on myocardial reperfusion injury.", AM HEART J, vol. 123, no. 2, 1992, pages 332 - 338 *
J.D. THORNTON: "Intravenous pretreatment with A1-selective adenosine analogues protects the heart against infarction.", CIRCULATION, vol. 85, no. 2, 1992, pages 659 - 665 *
M. KARMAZYN: "Adenosine A1 receptor activation attenuates cardiac injury produced by hydrogen peroxide.", CIRC. RES., vol. 71, no. 5, 1992, pages 1107 - 1110 *
M.F. GURDEN: "Functional characterization of three adenosine receptor types.", BR. J. PHARMACOL., vol. 109, no. 3, 1992, pages 693 - 698 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476351B1 (en) * 1996-01-05 2002-11-05 Lazare Kaplan International, Inc. Laser marking system
WO1999017784A1 (fr) * 1997-10-07 1999-04-15 Regents Of The University Of California Corporation Traitement de la vasculopathie peripherique obliterante et de la coronarite au moyen de conbinaisons d'heparine et d'un agoniste a2 adenosine, ou au moyen d'adenosine
US5972903A (en) * 1997-10-07 1999-10-26 Regents Of The University Of California Corporation Method for promoting angiogenesis using heparin and adenosine
US6440947B1 (en) 1997-10-07 2002-08-27 The Regents Of The University Of California Method for treating occlusive peripheral vascular disease and coronary disease
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists

Also Published As

Publication number Publication date
GB9421133D0 (en) 1994-12-07
AU3843495A (en) 1996-05-15

Similar Documents

Publication Publication Date Title
US4378347A (en) Composition for treating the heart for myocardial infarction
US4296100A (en) Method of treating the heart for myocardial infarction
Yun et al. Role of prostaglandins in the control of renin secretion in the dog.
CA2061270C (fr) Methode et appareil pour traiter les blessures de reperfusion
US5849763A (en) Use of levobupivacaine as an anesthetic agent
Trouve et al. Nitrendipine: an antidote to cardiac and lethal toxicity of cocaine
EP0627921A1 (fr) Procede d'inhibition de la carcinogenese a l'aide d'un traitement a la deshydroepiandrosterone et ses analogues
Herzog et al. Short-term low dose intracoronary diltiazem administered at the onset of reperfusion reduces myocardial infarct size
EP0344880B1 (fr) Compositions pharmaceutiques à activité anticancéreuse
DE69711649T2 (de) P1, p4-dithio-p2,p3-monochloromethylen 5',5'''-diadenosin-p1,p4-tetraphosphat verwendet als anti-thrombose mittel
Didolkar et al. Comparison of regional versus systemic chemotherapy with adriamycin
EP0610336B1 (fr) Traitement des troubles neurologiques a l'aide d'un compose inhibant l'interleukin-1
Perla et al. Prevention of histamine and surgical shock by cortical hormone (desoxycorticosterone acetate and cortin) and saline
JP3253302B2 (ja) ３−ジアルキルアミノエトキシベンゾイル−ベンゾフランを含有する非経口溶液
HU206186B (en) Process for producing pharmaceutical compositions comprising amino acid derivatives having ace-inhibiting effect
WO1996012496A1 (fr) Utilisation de n-[(1s,trans)-2-hydroxycyclopentyl]-adenosine pour reduire une blessure myocardique
CN113577051A (zh) 一种维拉帕米在制备保护软骨细胞缓解骨关节炎的产品中的应用
RU2432948C2 (ru) Применение активаторов растворимой гуанилатциклазы для лечения нарушений кровоснабжения
RU2252754C2 (ru) Применение карипорида для уменьшения нежелательных воздействий макролидных антибиотиков при ишемии и реперфузии сердца
US5585355A (en) Method for increasing blood-ocular barrier permeability with permeabilizer peptides
Stanford The stress response to trauma and critical illness
EP0366033A2 (fr) Méthode pour modifier le dysfonctionnement post-ischémique du myocarde en utilisant un inhibiteur de l'ACE seul ou en combinaison avec un agent thrombolytique, et la combinaison
CA2160689C (fr) Nouvelle methode de traitement
US5232950A (en) Method for using ketamine for prevention or reduction of the effects of stroke in a subject having increased risk for stroke
CN114796217B (zh) 一种含有西洛他唑的组合物在制备治疗脑血管病药物中的应用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA